The Oral Administration of Elastin Peptide Reduces Ultraviolet Light-Induced Photoaging in Hairless Mice

Mucinous tumors of the ovary, Specific AT sequence binding protein 2, Cytokeratin 20, Pathological typing, Prognostic outcome.This study aims to evaluate the co-expression of specific AT sequence binding protein 2 (SATB2 Group) and Cytokeratin 20 (CK20 Group) in mucinous ovarian tumors and their correlation with tumor pathological classification and prognostic outcome.One hundred and sixty cases of ovarian mucinous tumors diagnosed from January 2018 and January 2020 were selected.They were divided into four groups: mucinous cystadenocarcinoma group (age 62.78±7.92,n=53), borderline mucinous cystadenocarcinoma group (age 63.82±9.26,n=55), mucinous cystadenocarcinoma group (age 62.81±6.28,n=52) Group and normal ovarian group (age 62.71±7.97,n=160).All cases were examined by two gynecological pathologists.The expression levels of SATB2 and CK20 in different groups were detected by immunohistochemical staining.SATB2 in mucinous ovarian tumors had a diagnostic sensitivity of 82%, a specificity of 78%, and an overall accuracy rate of 82%.CK20 in mucinous ovarian tumors had a diagnostic sensitivity of 94%, a specificity of 59%, and an overall accuracy rate of 85%.SATB2/CK20 in mucinous ovarian tumors has a diagnostic sensitivity of 65%, a specificity of 99%, and an overall accuracy rate of 89%.Compared with SATB2/CK20 single staining, SATB2/CK20 double staining had lower sensitivity, higher specificity and increased overall accuracy.The expression levels of SATB2 and CK20 were not related to the patient's age, menstrual status and tumor diameter (P>0.05),but was related to recurrence, pathological type, tissue differentiation, prognostic outcome, disease course and clinical stage (P<0.05).According to immunohistochemical examination, the co-expression of SATB2 and CK20 could improve the specificity of mucinous ovarian tumors.In addition, SATB2/CK20 co-expression is related to recurrence, pathological type, tissue differentiation, prognostic outcome, disease course and clinical stage.